These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29762306)

  • 1. Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy: a systematic review protocol.
    Gwer SO; Onyango KO
    JBI Database System Rev Implement Rep; 2018 May; 16(5):1135-1140. PubMed ID: 29762306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
    Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
    Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of hydroxyurea in the management of sickle cell disease.
    Davies SC; Gilmore A
    Blood Rev; 2003 Jun; 17(2):99-109. PubMed ID: 12642122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
    Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
    Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 8. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
    Mvalo T; Topazian H; Kamthunzi P; Chen J; Kambalame I; Mafunga P; Mumba N; Chiume-Chiphaliwali M; Paseli K; Key N; Gopal S; Hoffman I; Ataga K; Westmoreland K
    Blood Adv; 2018 Nov; 2(Suppl 1):30-32. PubMed ID: 30504195
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease.
    Joseph L; Jean C; Manceau S; Chalas C; Arnaud C; Kamdem A; Pondarré C; Habibi A; Bernaudin F; Allali S; de Montalembert M; Boutonnat-Faucher B; Arlet JB; Koehl B; Cavazzana M; Ribeil JA; Lionnet F; Berthaut I; Brousse V
    Blood; 2021 Feb; 137(6):826-829. PubMed ID: 32976551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
    Italia KY; Jijina FF; Chandrakala S; Nadkarni AH; Sawant P; Ghosh K; Colah RB
    J Clin Pharmacol; 2010 Feb; 50(2):231-4. PubMed ID: 19797538
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K; Smith-Whitley K
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW; Kennedy LD
    Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
    Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
    Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia.
    Ballas SK; McCarthy WF; Guo N; DeCastro L; Bellevue R; Barton BA; Waclawiw MA;
    J Natl Med Assoc; 2009 Oct; 101(10):1046-51. PubMed ID: 19860305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Duffy null and its impact on hydroxyurea in young children with sickle cell disease in the United States.
    Oladipupo F; Stanek J; Walden J; Young J; Rose MJ; Nicol K; Villella A; Creary S
    Pediatr Blood Cancer; 2024 Jun; 71(6):e30945. PubMed ID: 38462769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea for the treatment of sickle cell anemia.
    Platt OS
    N Engl J Med; 2008 Mar; 358(13):1362-9. PubMed ID: 18367739
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences in quality of life between pediatric sickle cell patients who used hydroxyurea and those who did not.
    Nwenyi E; Leafman J; Mathieson K; Ezeobah N
    Int J Health Care Qual Assur; 2014; 27(6):468-81. PubMed ID: 25115050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal Screening and the Clinical Outcome in Children with Sickle Cell Disease in Central India.
    Upadhye DS; Jain DL; Trivedi YL; Nadkarni AH; Ghosh K; Colah RB
    PLoS One; 2016; 11(1):e0147081. PubMed ID: 26785407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
    Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.